ERL

Genius Group Announces 2023 Financial Results, 150% Pro Forma Revenue Growth to $70.4 million

Retrieved on: 
Mittwoch, Mai 15, 2024
Grand Canyon University, Student, CFO, Education, City, Pro forma, AI, Computer, Growth, Acquisition, ERL, Abu Dhabi University, Senior, Sales

Pro forma 2023 revenue increased 150% to $70.4 million from $28.1 million in 2022, including revenue from the FatBrain AI transaction.

Key Points: 
  • Pro forma 2023 revenue increased 150% to $70.4 million from $28.1 million in 2022, including revenue from the FatBrain AI transaction.
  • Gross profit increased to $11.9 million or 52% of revenue compared to $8.6 million, or 47% of revenue in 2022.
  • Gross profit increased to $11.9 million or 52% of revenue compared to $8.6 million, or 47% or revenue in 2022.
  • During the year ended December 31, 2023, overall pro forma revenue totaled $70.4 million, compared to $28.1 million in 2022.

Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Dienstag, Mai 7, 2024
Sale, FDA, University, Lupus nephritis, CRISPR, Food, Rachel Haurwitz, Poster, Research, HLA, Reindeer, MD, Doctor of Philosophy, Huntsman Cancer Institute, Amplification, AML, Leukemia, ERL, IND, ASCO, Lymphoma, Patent, Pfizer, CLL, Patient, Society, G&A, MD Anderson Cancer Center, Lupus, Annual general meeting, Investigational New Drug, Pharmaceutical industry

BERKELEY, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for the first quarter 2024 and reviewed recent pipeline progress.

Key Points: 
  • The update will include:
    CB-010 GALLOP: Caribou plans to initiate the GALLOP Phase 1 clinical trial in adult patients with LN and ERL by year-end 2024.
  • CB-011 CaMMouflage: Caribou plans to present initial dose escalation data from the ongoing CaMMouflage Phase 1 clinical trial by year-end 2024.
  • CB-012 AMpLify: Caribou plans to provide updates on dose escalation as the AMpLify Phase 1 clinical trial in r/r AML advances.
  • Net loss: Caribou reported a net loss of $41.2 million for the three months ended March 31, 2024, compared to $28.0 million for the same period in 2023.

Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus

Retrieved on: 
Donnerstag, April 4, 2024
Logic, LN, Transplant, Medical College of Wisconsin, Rachel Haurwitz, Infection, Lupus, Risk, Medical college, Patient, Inflammation, Tissue, Autoimmune disease, Standard of care, Doctor of Philosophy, MD, Autoantibody, IND, Congress, HLA, Reindeer, Antibody, CRISPR, Safety, Immune system, Fatigue, FDA, Lupus nephritis, Autoimmunity, Bone marrow, ERL, Medicine, CD19, Food, PD-1, Pharmaceutical industry

BERKELEY, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for CB-010, an allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (KO), for the treatment of lupus nephritis (LN) and extrarenal lupus (ERL). The Phase 1, multicenter, open label GALLOP clinical trial of CB-010 in patients with LN and ERL is expected to initiate by year-end 2024.

Key Points: 
  • The Phase 1, multicenter, open label GALLOP clinical trial of CB-010 in patients with LN and ERL is expected to initiate by year-end 2024.
  • CB-010 targets CD19, a protein on the surface of B cells, and has a PD-1 knockout (KO) that reduces CAR-T cell exhaustion.
  • CB-010 holds the potential for deep depletion of disease-causing B cells which could reset the immune system, leading to sustained drug-free remission.
  • Instead, the chRDNA technology allows for precise insertion of the CAR at an intended location within the T cell genome.

SSENSE CELEBRATES 20 YEARS WITH THE LAUNCH OF SSENSE XX

Retrieved on: 
Mittwoch, Oktober 4, 2023
SSENSE, Elder, Friends, Culture, Acne Studios, Wales, Old Port, Commerce, XX, ERL, Salomon, New Balance

SSENSE XX puts a spotlight on friends and collaborators — past, present and future — who have played a formative role in the SSENSE brand story.

Key Points: 
  • SSENSE XX puts a spotlight on friends and collaborators — past, present and future — who have played a formative role in the SSENSE brand story.
  • "Through SSENSE XX, we're continuing to push the conversation around fashion, community and culture forward through product, content and experiences."
  • A physical manifestation of SSENSE XX will live at SSENSE MONTRÉAL , the brand's flagship store located at 418 St. Sulpice Street in Montreal's Old Port.
  • Exclusive SSENSE XX merchandise will be available in limited quantities starting October 23 on ssense.com and the SSENSE mobile app.

SSENSE CELEBRATES 20 YEARS WITH THE LAUNCH OF SSENSE XX

Retrieved on: 
Mittwoch, Oktober 4, 2023
SSENSE, Elder, Friends, Culture, Acne Studios, Wales, Old Port, Commerce, XX, ERL, Salomon, New Balance

SSENSE XX puts a spotlight on friends and collaborators — past, present and future — who have played a formative role in the SSENSE brand story.

Key Points: 
  • SSENSE XX puts a spotlight on friends and collaborators — past, present and future — who have played a formative role in the SSENSE brand story.
  • "Through SSENSE XX, we're continuing to push the conversation around fashion, community and culture forward through product, content and experiences."
  • A physical manifestation of SSENSE XX will live at SSENSE MONTRÉAL , the brand's flagship store located at 418 St. Sulpice Street in Montreal's Old Port.
  • Exclusive SSENSE XX merchandise will be available in limited quantities starting October 23 on ssense.com and the SSENSE mobile app.

Genius Group Provides Update on ERL Spinoff

Retrieved on: 
Montag, September 25, 2023
ERL, Upstream, NYSE, Cryptocurrency

SINGAPORE, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Genius Group Limited (NYSE American: GNS) (“Genius Group” or the “Company”), a leading entrepreneur edtech and education group, announces that the commencement date to claim the Entrepreneur Resorts Ltd (“ERL”) spinoff shares is on September 26, 2023, with the distribution date for the spinoff shares to commence on October 2, 2023.

Key Points: 
  • SINGAPORE, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Genius Group Limited (NYSE American: GNS) (“Genius Group” or the “Company”), a leading entrepreneur edtech and education group, announces that the commencement date to claim the Entrepreneur Resorts Ltd (“ERL”) spinoff shares is on September 26, 2023, with the distribution date for the spinoff shares to commence on October 2, 2023.
  • Shareholders can find detailed instructions on how to claim their ERL shares on the ERL Investor Relations website .
  • All Genius Group shareholders entitled to the dividend will receive restricted shares in ERL, which may be eligible for removal of restrictions beginning six months after the share distribution date, if certain requirements are met.
  • Genius Group will have no further contact with Upstream as a result of the previously announced delisting.

Genius Group Announces Delisting from Upstream

Retrieved on: 
Dienstag, September 19, 2023
Transfer, Ticker symbol, Non-fungible token, DRS, ERL, NYSE, Security (finance), Upstream

SINGAPORE, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Genius Group Limited (NYSE American: GNS) (“Genius Group” or the “Company”), a leading entrepreneur edtech and education group, announces that it will delist its shares from Upstream, the trading app for digital securities and NFTs powered by Horizon Fintex.

Key Points: 
  • SINGAPORE, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Genius Group Limited (NYSE American: GNS) (“Genius Group” or the “Company”), a leading entrepreneur edtech and education group, announces that it will delist its shares from Upstream, the trading app for digital securities and NFTs powered by Horizon Fintex.
  • The decision to delist the Company from Upstream is due to complex securities regulations arising from the dual listing on Upstream and NYSE.
  • The delisting process was commenced today and will be complete on or about September 29, 2023.
  • Genius Group will have no further contact with Upstream as a result of this delisting.

Genius Group Announces that ERL is Approved to List on Upstream

Retrieved on: 
Freitag, September 15, 2023
ERL, NYSE, Rare-earth element, Information technology, Upstream

SINGAPORE, Sept. 15, 2023 (GLOBE NEWSWIRE) -- Genius Group Limited (NYSE American: GNS) (“Genius Group” or the “Company”), a leading entrepreneur edtech and education group, announces that its subsidiary Entrepreneur Resorts Ltd (“ERL”) has been approved to change its listing from the main board of MERJ Exchange to Upstream, a new MERJ Exchange market.

Key Points: 
  • SINGAPORE, Sept. 15, 2023 (GLOBE NEWSWIRE) -- Genius Group Limited (NYSE American: GNS) (“Genius Group” or the “Company”), a leading entrepreneur edtech and education group, announces that its subsidiary Entrepreneur Resorts Ltd (“ERL”) has been approved to change its listing from the main board of MERJ Exchange to Upstream, a new MERJ Exchange market.
  • ERL will commence trading on Upstream on September 25, 2023.

Genius Group Announces Spinoff Ratio

Retrieved on: 
Dienstag, September 5, 2023
ERL, NYSE, Tutoring, Security (finance), Bank

SINGAPORE, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Genius Group Limited (NYSE American: GNS) (“Genius Group” or the “Company”), a leading entrepreneur edtech and education group, announces that the distribution ratio for the spinoff of Entrepreneur Resorts Ltd (“ERL”) is 0.1832.

Key Points: 
  • SINGAPORE, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Genius Group Limited (NYSE American: GNS) (“Genius Group” or the “Company”), a leading entrepreneur edtech and education group, announces that the distribution ratio for the spinoff of Entrepreneur Resorts Ltd (“ERL”) is 0.1832.
  • Shareholders can find detailed instructions on how to claim their ERL shares on our Investor Relations website .
  • Genius Group will announce further updates in the coming weeks as to the date they can start claiming ERL shares and confirm the share distribution date, which is expected to be on or about September 29, 2023.
  • All shareholders will receive restricted shares in ERL, which may be eligible for removal of restrictions and traded on Upstream six months after the share distribution date, if certain requirements are met.

Genius Group Announces Record Date for Spinoff

Retrieved on: 
Montag, August 7, 2023
Non-use value, High Court of Singapore, Ticker, NYSE American, ERL, NYSE, Security (finance), Upstream

SINGAPORE, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Genius Group Limited (NYSE American: GNS) (“Genius Group” or the “Company”), a leading entrepreneur edtech and education group, announces the timeline, record date and share distribution date for the spinoff of Entrepreneur Resorts Ltd (“ERL”).

Key Points: 
  • SINGAPORE, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Genius Group Limited (NYSE American: GNS) (“Genius Group” or the “Company”), a leading entrepreneur edtech and education group, announces the timeline, record date and share distribution date for the spinoff of Entrepreneur Resorts Ltd (“ERL”).
  • On August 1, 2023, the Singapore High Court approved the spinoff of ERL from Genius Group, with a capital reduction and share distribution to all Genius Group shareholders at the record date of US$38,380,873 in the form of restricted ordinary shares in ERL, pursuant to a private placement transaction exempt from registration under the provisions of the Securities Act of 1933, as amended.
  • Genius Group has set the record date for a full share count of its shares for the purpose of the distribution as August 31, 2023.
  • Following the share distribution, shares of Genius Group and ERL will trade as securities of two separate public companies, with Genius Group dual listed on NYSE American and Upstream (Ticker: GNS), and ERL listed on Upstream (Ticker: ERL).